Zealand Pharma, a biotechnology company, presented data for their amylin analog ZP8396 at the Obesity Society Annual Meeting (ObesityWeek) in Dallas, Texas. The clinical results showcased the potential of ZP8396 as a next-generation treatment for overweight and obesity, offering weight loss comparable to GLP-1 based therapies with improved tolerability. These results were from a 6-week multiple ascending dose (MAD) clinical trial.
In this trial, low doses of ZP8396 reduced body weight by up to 5.3% in both healthy lean and overweight participants. ZP8396 was found to be safe and well-tolerated. Additionally, combining ZP8396 with the GLP-1/GIP dual agonist tirzepatide in a preclinical model resulted in even greater weight loss, supporting the potential for combined treatment for people with overweight and obesity.
The MAD trial consisted of two parts, involving both normal-weight and overweight participants. ZP8396 is an investigational amylin analog designed to improve solubility and minimize fibrillation, with promising results in preclinical models and clinical trials.
Zealand Pharma is a biotech company focused on peptide-based medicines and has several drug candidates in development, with two already on the market and others in late-stage development.
Please note that the information provided is based on a press release from October 17, 2023, and the data presented at the Obesity Society Annual Meeting.